Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339634 · ClinicalTrials.gov registry record
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
A clinical trial, sponsored by Tabula Rasa HealthCare.
- Completed
- Registry status
- 12,873
- Enrollment target
NCT04339634 is a clinical trial that has completed, run by Tabula Rasa HealthCare. The registered enrollment target is 12,873 participants.
The verdict
NCT04339634 has completed, sponsored by Tabula Rasa HealthCare.
- COMPLETED
- Registry status
- 12,873 participants
- Enrollment target
Study Summary
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled in PACE organizations. Our clinical tool would enable to identify potential multi-drug interactions and potentially reduce the risk of adverse drug events (ADE) developing in elderly patients infected with COVID-19.
Interventions
- OTHER Simulation of Repurposed Drugs for COVID-19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,873 participants |
| Start Date | 2020-04-02 |
| Est. Completion | 2023-01-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04339634
The ClinicalTrials.gov registry entry for NCT04339634 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12,873 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tabula Rasa HealthCare, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Simulation of Repurposed Drugs for COVID-19 is the first listed.
NCT04339634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04339634 about?
NCT04339634 is a clinical study titled "Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy". This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled in PACE organizations. Our clinical tool would enable to identify pote...
What is the current status of trial NCT04339634?
This trial is currently completed. The enrollment target is 12,873 participants. The study started on 2020-04-02. Estimated completion is 2023-01-30.
What interventions are being tested in trial NCT04339634?
The interventions under investigation include: Simulation of Repurposed Drugs for COVID-19 (OTHER).
Who is sponsoring clinical trial NCT04339634?
This trial is sponsored by Tabula Rasa HealthCare, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.